Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06649136 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis

Study acronym: MethMax
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Sep 30, 2026 → Jun 7, 2027
See other at-risk trials from Medical University of Vienna

Record History

  1. Primary and study completion pushed from Sep 30, 2026 to Jun 7, 2027 Eligibility criteria expanded, about 57 words · Secondary endpoints: details revised at 4 of 15 entries · Study description revised · 2 more Show 5 more changesShow less
    • Eligibility criteria expanded, about 57 words
    • Secondary endpoints: details revised at 4 of 15 entries
    • Study description revised
    • Site contact updated
    • Collaborators: 4 to 6
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The MethMax trial is a prospective, international, multicentre, randomised, assessor-blinded, parallel-group, low intervention study. Patients with active rheumatoid arthritis treated with oral methotrexate up to 25 mg weekly will be randomised in 50:50 fashion to receive 25 mg oral vs subcutaneous methotrexate for the period of 24 weeks. In regular visits, patient reported outcomes, clinical disease activity, therapy adherence and diverse established and exploratory biomarkers will be assessed.
Trial Details
NCT Number NCT06649136
Lead Sponsor Medical University of Vienna
Collaborators: Leiden University Medical Center, Queen Mary University of London, Carol Davila University of Medicine and Pharmacy, Clinical Centre for Rheumatic Diseases, Bucharest, Humanitas Mirasole S.p.A. - Instituto Clinico Humanitas (ICH), Rozzano (Milan), Region Stockholm, Solna, Diakonhjemmet Hospital AS (DH), Oslo
Conditions Rheumatoid Arthritis
Enrollment 182 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov